PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1121973
Abstract: Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to… read more here.
Keywords: cell; ovarian cancer; tcrs; prame ctcfl ... See more keywords